Form 4: Oruka Therapeutics CMO Executes Stock Transactions

Oruka Therapeutics Chief Medical Officer Joana Goncalves exercised stock options and sold shares under a 10b5-1 plan.

Summary

• Chief Medical Officer Joana Goncalves exercised options to acquire 3,500 shares at $6.84 and 3,500 shares at $7.80.
• A total of 7,947 shares were sold in multiple transactions at weighted average prices ranging from $68.38 to $70.62.
• The sales were conducted pursuant to a Rule 10b5-1 trading plan established on September 19, 2025.
• A portion of the shares (947) were sold via an automatic sell-to-cover procedure to satisfy tax withholding obligations.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the transactions were executed under a pre-existing 10b5-1 plan and include mandatory tax-related selling.

Positives

• The executive maintains a significant remaining beneficial ownership of 32,718 shares following the transactions.
• The transactions were executed under a pre-established Rule 10b5-1 trading plan, indicating systematic rather than discretionary selling.

Negatives

• The executive reduced their direct holdings in the company through the sale of 7,947 shares.

Risks

• Future share price volatility could impact the value of remaining holdings.
• Reliance on Rule 10b5-1 plans does not eliminate market risk for the reporting person.

Future Outlook

No specific forward-looking guidance regarding company operations was provided in this filing.

Industry Context

StockSavvy.ai notes that insider selling via 10b5-1 plans is a standard practice for executives to manage personal liquidity and tax obligations, and is generally viewed as neutral by the market when pre-planned.

Comparison to Industry Standards

• The use of Rule 10b5-1 plans is consistent with standard corporate governance practices for executives in the biotechnology sector.

Stakeholder Impact

• Minimal impact expected as the transactions were pre-planned and represent a small portion of the executive's total holdings.

Next Steps

• Continued monitoring of future Form 4 filings for further insider activity.

Key Dates

Keywords

Oruka Therapeutics, ORKA, Insider Trading, Form 4, Chief Medical Officer, Stock Options, 10b5-1